camptothecin has been researched along with Rhabdomyosarcoma in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.14) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 12 (34.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahrami, A; Blankenship, K; Bradley, C; Chen, X; Clay, MR; Dapper, J; Downing, J; Dyer, MA; Easton, J; Federico, SM; Freeman, BB; Gordon, B; Honnell, V; Karlstrom, A; Mardis, ER; Ocarz, M; Pappo, A; Shelat, AA; Stewart, E; Twarog, NR; Wilson, RK; Wu, J; Xu, B; Zhang, J; Zhou, X | 1 |
| Aparicio, S; Boerkoel, CF; Bond, M; Choi, K; Chowdhury, M; Fam, HK; Mitra, SA; O'Sullivan, MJ; Osborne, N; Pallen, CJ; Sun, G; Triche, TJ; Turashvili, G; Walton, C; Wong, PC | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Deng, D; Fang, HB; Tan, M; Zhang, T | 1 |
| Barth, S; Brehm, H; Fischer, R; Hristodorov, D; Mladenov, R; Niesen, J; Pardo, A; Tur, MK | 1 |
| Anderson, JR; Arndt, CA; Hawkins, DS; Lyden, E; Meyer, WH; Michalski, JM; Parham, DM; Rodeberg, DA; Weigel, BJ | 1 |
| Baumgart, JT; Edessa, LD; Helman, LJ; Heske, CM; Lee, S; Mendoza, A; Neckers, L; Proia, DA; Trepel, J | 1 |
| Cusano, G; D'Incalci, M; Di Francesco, AM; Forestieri, D; Meco, D; Patriarca, V; Pisano, C; Riccardi, R; Servidei, T; Zucchetti, M | 1 |
| Anderson, JR; Breitfeld, PP; Donaldson, SS; Hawkins, DS; Lyden, ER; Mascarenhas, L; Meyer, WH; Paidas, CN; Parham, DM; Walterhouse, DO | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Bucci, F; Cassinelli, G; Cominetti, D; De Cesare, M; Di Francesco, AM; Lanzi, C; Meco, D; Orlandi, A; Passeri, D; Petrangolini, G; Pisano, C; Riccardi, R; Tortoreto, M; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Dharmarajan, KV; Wexler, LH; Wolden, SL | 1 |
| Ahmed, B; De Boeck, G; de Bruijn, EA; Guetens, G; Landuyt, W; van Oosterom, AT; Wildiers, H | 1 |
| Liang, H; Sha, N | 1 |
| Fang, HB; Houghton, PJ; Tan, M; Tian, GL | 1 |
| Cheshire, PJ; Danks, MK; Houghton, PJ; Hyatt, JL; Iacono, L; Morton, CL; Potter, PM; Stewart, CF; Taylor, KR | 1 |
| Morikawa, Y | 1 |
| D'Incalci, M; Faircloth, GT; Jimeno, J; Marabese, M; Mazzarella, G; Meco, D; Riccardi, A; Riccardi, R; Ubezio, P | 1 |
| Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M | 1 |
| Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
| Gupta, AA; Pappo, AS | 1 |
| Assadourian, S; Bergeron, C; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Morland, B; Orbach, D; Pichon, F; Picton, S; Stockdale, E; Vassal, G | 1 |
| Breitfeld, P; Crews, KR; Donaldson, SS; Houghton, P; Lyden, E; Meyer, WH; Pappo, AS; Parham, D; Wiener, E | 1 |
| Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
| Ali-Osman, F; Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Griffith, OW; Kaufmann, SH; Moschel, RC; Schold, SC | 1 |
| Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A | 1 |
| Danks, MK; Morton, CL; Pawlik, CA; Potter, PM | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| Danks, MK; Guichard, SM; Harris, LC; Iyengar, RV; Khanna, R; Krull, EJ; Mason, SE; Pawlik, CA; Potter, PM | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Burger, RA; Danks, MK; Harris, LC; Iyengar, RV; Krull, EJ; Pawlik, CA; Phelps, DA; Potter, PM | 1 |
| Danks, MK; Harris, LC; Morton, CL; Potter, PM; Weeks, JK; Wierdl, M | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Houghton, PJ; Santana, VM | 1 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Myers, L; Stewart, CF; Synold, TW | 1 |
4 review(s) available for camptothecin and Rhabdomyosarcoma
| Article | Year |
|---|---|
[Childhood rhabdomyosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Humans; Irinotecan; Radiotherapy Dosage; Rhabdomyosarcoma; Risk; Vincristine | 2005 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2006 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
7 trial(s) available for camptothecin and Rhabdomyosarcoma
| Article | Year |
|---|---|
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vincristine | 2016 |
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Recurrence; Rhabdomyosarcoma; Risk Factors; Time Factors; Treatment Outcome; United States; Vincristine | 2010 |
Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Child; Female; Humans; Irinotecan; Male; Pilot Projects; Rhabdomyosarcoma; Soft Tissue Neoplasms | 2013 |
Irinotecan for children with relapsed solid tumors.
Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor | 2006 |
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Rhabdomyosarcoma; Survival Analysis; Treatment Outcome | 2007 |
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Metastasis; Rhabdomyosarcoma; Treatment Outcome; Vincristine | 2007 |
24 other study(ies) available for camptothecin and Rhabdomyosarcoma
| Article | Year |
|---|---|
Orthotopic patient-derived xenografts of paediatric solid tumours.
Topics: Animals; Bortezomib; Camptothecin; Cell Cycle Proteins; Child; Clone Cells; Drug Therapy, Combination; Epigenesis, Genetic; Female; Heterografts; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Indoles; Irinotecan; Mice; Neoplasms; Nuclear Proteins; Panobinostat; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2017 |
TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Camptothecin; Cell Line, Tumor; Child; DNA Repair; Gene Expression Profiling; Gene Knockout Techniques; Glucose; Humans; Mutation; Myoblasts, Skeletal; Phosphoric Diester Hydrolases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rhabdomyosarcoma; Serum; Tissue Array Analysis | 2013 |
Modeling sustained treatment effects in tumor xenograft experiments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Interactions; Humans; Irinotecan; Mice; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.
Topics: Apoptosis; Camptothecin; Cell Line, Tumor; Cholinergic Antagonists; Escherichia coli; Humans; Immunotherapy; Microtubule-Associated Proteins; Protein Binding; Receptors, Cholinergic; Recombinant Fusion Proteins; Rhabdomyosarcoma; U937 Cells | 2015 |
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Resorcinols; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Rhabdomyosarcoma; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; DNA Topoisomerases, Type I; Female; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Mice, Nude; Pyrroles; Receptors, Scavenger; Rhabdomyosarcoma; Sarcoma; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Drug Interactions; Drug Synergism; Humans; Irinotecan; Neoplasm Transplantation; Rats; Rhabdomyosarcoma; Stilbenes; Time Factors; Tumor Cells, Cultured | 2004 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Likelihood Functions; Longitudinal Studies; Mice; Mice, SCID; Models, Biological; Models, Statistical; Neoplasms, Experimental; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2005 |
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Dose-Response Relationship, Drug; Esterases; Gastrointestinal Tract; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Transplantation; Rhabdomyosarcoma; Sarcoma, Experimental | 2005 |
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dioxoles; DNA Topoisomerases, Type I; Humans; In Vitro Techniques; Irinotecan; Isoquinolines; Male; Mice; Mice, Nude; Rhabdomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Camptothecin; Carmustine; DNA Polymerase I; DNA Polymerase II; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Male; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Rhabdomyosarcoma; Topotecan; Transferases; Transplantation, Heterologous | 1994 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1993 |
Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Cell Division; Drug Screening Assays, Antitumor; Humans; Irinotecan; Liver; Prodrugs; Rabbits; Rhabdomyosarcoma; Tumor Cells, Cultured | 1998 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Topics: Animals; Blotting, Northern; Blotting, Southern; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Genetic Vectors; Humans; Irinotecan; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Tumor Cells, Cultured | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Glioblastoma; Humans; Immunoblotting; Irinotecan; MyoD Protein; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Transgenes; Tumor Cells, Cultured | 2001 |
Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; DNA, Complementary; Drug Screening Assays, Antitumor; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Liver; Rabbits; Rhabdomyosarcoma; Transduction, Genetic; Tumor Cells, Cultured | 2001 |
Clinical trials using irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2002 |
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Camptothecin; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Osteosarcoma; Remission Induction; Rhabdomyosarcoma; Time Factors; Topotecan; Tumor Cells, Cultured | 1992 |